Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer

International Journal of Cancer

Volumn 137, Issue 9, 2015, Pages 2072-2082

  Hubaux, Roland ^a   Thu, Kelsie L ^a   Vucic, Emily A ^a   Pikor, Larissa A ^a   Kung, Sonia H Y ^a   Martinez, Victor D ^a   Mosslemi, Mitra ^a   Becker Santos, Daiana D ^a   Gazdar, Adi F ^b   Lam, Stephen ^a   Lam, Wan L ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cisplatin resistance; DNA damage repair; lung cancer; MARK2; NF B

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAX PROTEIN; MICROTUBULE AFFINITY REGULATING KINASE 2; MYC PROTEIN; PROTEIN KINASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MARK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; ENZYME ACTIVITY; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MARK2 GENE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; ENZYMOLOGY; LUNG NEOPLASMS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES;

EID: 84939588821     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29577     Document Type: Article

References (36)

1. Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman DD, Bray F,. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
2. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
3. Consortia TCGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
4. Consortia TCGA. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
5. Pikor LA, Ramnarine VR, Lam S, Lam WL,. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 2013; 82: 179-89.
6. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E,. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997; 89: 297-308.
7. Matenia D, Mandelkow EM,. The tau of MARK: a polarized view of the cytoskeleton. Trend Biochem Sci 2009; 34: 332-42.
8. Kato T, Satoh S, Okabe H, et al., Isolation of a novel human gene, markl1, homologous to mark3 and its involvement in hepatocellular carcinogenesis. Neoplasia 2001; 3: 4-9.
9. Wu ZZ, Lu HP, Chao CC,. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol 2010; 80: 262-76.
10. Almeida GM, Duarte TL, Farmer PB, et al., Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer 2008; 122: 1810-9.
11. Gansukh T, Donizy P, Halon A, et al., In Vitro analysis of the relationships between metallothionein expression and cisplatin sensitivity of Non-small cellular lung cancer cells. Anticancer Res 2013; 33: 5255-60.
12. van de Vaart PJ, Belderbos J, de Jong D, et al., DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-6.
13. Thu KL, Vucic EA, Chari R, et al., Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PloS One 2012; 7: e33003
14. Wilson IM, Vucic EA, Enfield KS, et al., Eya4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene 2014; 33: 4464-73.
15. Yang W, Soares J, Greninger P, et al., Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-61.
16. Ramirez RD, Sheridan S, Girard L, et al., Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004; 64: 9027-34.
17. Panneerselvam S, Marx A, Mandelkow EM, Mandelkow E,. Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. Structure. 2006; 14: 173-83.
18. Hubaux R, Thu KL, Coe BP, et al., Ezh2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. J Thoracic Oncol 2013; 8: 1102-6.
19. Thu KL, Pikor LA, Chari R, et al., Genetic disruption of keap1/cul3 e3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. J Thoracic Oncol 2011; 6: 1521
20. Lockwood WW, Chari R, Coe BP, et al., Integrative genomic analyses identify brf2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS Med 2010; 7: e1000315
21. Pikor LA, Lockwood WW, Thu KL, et al., Yeats4 is a novel oncogene amplified in Non-small cell lung cancer that regulates the p53 pathway. Cancer Res 2013; 73: 7301-12.
22. Huang X, Okafuji M, Traganos F, et al., Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry Part A 2004; 58: 99-110.
23. Subramanian A, Tamayo P, Mootha VK, et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545-50.
24. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-21.
25. Timm T, von Kries JP, Li X, et al., Microtubule affinity regulating kinase activity in living neurons was examined by a genetically encoded fluorescence resonance energy transfer/fluorescence lifetime imaging-based biosensor: inhibitors with therapeutic potential. J Biol Chem 2011; 286: 41711-22.
26. Janssens S, Tschopp J,. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Diff 2006; 13: 773-84.
27. Rogakou EP, Pilch DR, Orr AH, et al., DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858-68.
28. Garcia-Canton C, Anadon A, Meredith C,. gammaH2AX as a novel endpoint to detect DNA damage: applications for the assessment of the in vitro genotoxicity of cigarette smoke. Toxicol In Vitro 2012; 26: 1075-86.
29. Traweger A, Wiggin G, Taylor L, et al., Protein phosphatase 1 regulates the phosphorylation state of the polarity scaffold Par-3. Proc Natl Acad Sci U S A 2008; 105: 10402-7.
30. Sapir T, Sapoznik S, Levy T, et al., Accurate balance of the polarity kinase mark2/Par-1 is required for proper cortical neuronal migration. J Neurosci 2008; 28: 5710-20.
31. Sun TQ, Lu B, Feng JJ, et al., PAR-1 is a Dishevelled-associated kinase and a positive regulator of wnt signalling. Nat Cell Biol 2001; 3: 628-36.
32. Mamidi A, Inui M, Manfrin A, et al., Signaling crosstalk between TGFbeta and dishevelled/Par1b. Cell Death Diff 2012; 19: 1689-97.
33. Ossipova O, Dhawan S, Sokol S, Green JB,. Distinct PAR-1 proteins function in different branches of wnt signaling during vertebrate development. Dev Cell 2005; 8: 829-41.
34. Benkemoun L, Descoteaux C, Chartier NT, et al., PAR-4/lkb1 regulates DNA replication during asynchronous division of the early C. Elegans embryo. J Cell Biol 2014; 205: 447-55.
35. Perkins ND,. NF-kappaB: tumor promoter or suppressor? Trend Cell Biol 2004; 14: 64-9.
36. Radhakrishnan SK, Kamalakaran S,. Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim Biophys Acta 2006; 1766: 53-62.